Treatment of lentigo maligna (melanoma in situ) with the immune response modifier imiquimod

Archives of Dermatology

Volumn 141, Issue 4, 2005, Pages 510-514

  Wolf, Ingrid H ^a   Cerroni, Lorenzo ^a   Kodama, Kazuo ^b   Kerl, Helmut ^a  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

^b HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

IMIQUIMOD;

AGED; ARTICLE; CELL MEDIATED CYTOTOXICITY; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DRUG RESPONSE; FEMALE; HELPER CELL; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNE RESPONSE; IMMUNOHISTOLOGY; MALE; MALIGNANT LENTIGO; PRIORITY JOURNAL; SKIN BIOPSY; SURGICAL RISK;

ADJUVANTS, IMMUNOLOGIC; AGED; AGED, 80 AND OVER; AMINOQUINOLINES; BIOPSY, NEEDLE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; HUTCHINSON'S MELANOTIC FRECKLE; IMMUNOHISTOCHEMISTRY; MALE; PILOT PROJECTS; RISK ASSESSMENT; SINGLE-BLIND METHOD; SKIN NEOPLASMS; TREATMENT OUTCOME;

EID: 17444378895     PISSN: 0003987X     EISSN: None     Source Type: Journal    
DOI: 10.1001/archderm.141.4.510     Document Type: Article

References (19)

1. Cerroni L, Smolle J, Soyer HP, Martinez Aparicio A, Kerl H. Immunophenotyping of cutaneous lymphoid infiltrates in frozen and paraffin-embedded tissue sections: a comparative study. J Am Acad Dermatol. 1990;22:405-413.
2. Ahmed I, Berth-Jones J. Imiquimod: a novel treatment for lentigo maligna. Br J Dermatol. 2000;143:843-845.
3. Borucki U, Metze D. Topical treatment of lentigo maligna melanoma with imiquimod 5% cream. Dermatology. 2003;207:326-328.
4. Chapman MS, Spencer SK, Brennick JB. Histologic resolution of melanoma in situ (lentigo maligna) with 5% imiquimod cream. Arch Dermatol. 2003;139:943-944.
5. Epstein E. Extensive lentigo maligna clearing with topical imiquimod. Arch Dermatol. 2003;139:944-945.
6. Fisher GH, Lang PG. Treatment of melanoma in situ on sun-damaged skin with topical 5% imiquimod cream complicated by the development of invasive disease. Arch Dermatol. 2003;139:945-947.
7. Powell AM, Russel-Jones R, Barlow RJ. Topical imiquimod immunotherapy in the management of lentigo maligna. Clin Exp Dermatol. 2004;29:15-21.
8. Wolf IH, Smolle J, Binder B, Cerroni L, Richtig E, Kerl H. Topical imiquimod in the treatment of metastatic melanoma to skin. Arch Dermatol. 2003;139:273-276.
9. Naylor MF, Crowson N, Kuwahara R, et al. Treatment of lentigo maligna with topical imiquimod. Br J Dermatol. 2003;149(suppl 66):66-69.
10. Hurwitz DJ, Pincus L, Kupper TS. Imiquimod: a topically applied link between innate and acquired immunity. Arch Dermatol. 2003;139:1347-1350.
11. Schwarz K, Storni T, Manolova V, et al. Role of Toll-like receptors in costimulating cytotoxic T cell responses. Eur J Immunol. 2003;33:1465-1470.
12. Stanley MA. Imiquimod and the imidazoquinolones: mechanism of action and therapeutic potential. Clin Exp Dermatol. 2002;27:571-577.
13. Sauder DN. Imiquimod: modes of action. Br J Dermatol. 2003;149(suppl 66):5-8.
14. Urosevic M, Maier T, Benninghoff B, Slade H, Burg G, Dummer R. Mechanisms underlying imiquimod-induced regression of basal cell carcinoma in vivo. Arch Dermatol. 2003;139:1325-1332.
15. Suzuki H, Wang B, Shivji GM, et al. Imiquimod, a topical immune response modifier, induces migration of Langerhans cells. J Invest Dermatol. 2000;114:135-141.
16. Schon M, Bong AB, Drewniok C, et al. Tumor-selective induction of apoptosis and the small-molecular immune response modifier imiquimod. J Natl Cancer Inst. 2003;95:1138-1149.
17. Sidbury R, Neuschler N, Neuschler E, et al. Topically applied imiquimod inhibits vascular tumor growth in vivo. J Invest Dermatol. 2003;121:1205-1209.
18. Sullivan TP, Dearaujo T, Vincek V, Berman B. Evaluation of superficial basal cell carcinomas after treatment with imiquimod 5% cream or vehicle for apoptosis and lymphocyte phenotyping. Dermatol Surg. 2003;29:1181-1186.
19. Hermanns-Le T, Paquet Ph, Nikkels AF, Franchimont CP, Pierard GE. Prolonged imiquimod treatment and graft-versus host reaction: histological mimicry in the skin infiltration pattern of the monocyte-macrophage-dendrocyte lineage. Dermatology. 2003;206:361-365.